Fatal hepatitis during Epstein-Barr virus reactivation

European Review for Medical and Pharmacological Sciences

Volumn 7, Issue 4, 2003, Pages 107-109

  Cacopardo, B ^a   Nunnari, G ^a   Mughini, M T ^a   Tosto, S ^a   Benanti, F ^a   Nigro, L ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Epstein Barr virus; Fulminant hepatitis; Reactivation; Steroids

Indexed keywords

ACICLOVIR; AMINOTRANSFERASE; EPSTEIN BARR VIRUS ANTIGEN; FRESH FROZEN PLASMA; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LACTULOSE; METHYLPREDNISOLONE; NEOMYCIN; OMEPRAZOLE; STEROID; VIRUS CAPSID ANTIGEN;

ADULT; ANAMNESIS; ANTIBODY TITER; ARTHRALGIA; ARTICLE; CASE REPORT; DEATH; DISEASE COURSE; DRUG USE; DRUG WITHDRAWAL; ECHOGRAPHY; EPSTEIN BARR VIRUS; FATIGUE; FEVER; HEPATIC ENCEPHALOPATHY; HEPATITIS; HOSPITAL ADMISSION; HUMAN; INFECTIOUS MONONUCLEOSIS; INTENSIVE CARE UNIT; JAUNDICE; LABORATORY TEST; LIVER FAILURE; MALAISE; MALE; PATHOGENESIS; POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; VIRUS LOAD; VIRUS REACTIVATION;

ADMINISTRATION, ORAL; ADULT; ARTHRALGIA; FATAL OUTCOME; FATIGUE; HEPATIC ENCEPHALOPATHY; HERPESVIRUS 4, HUMAN; HUMANS; JAUNDICE; MALE; METHYLPREDNISOLONE; VIRUS ACTIVATION;

EID: 1342308661     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Shaw N.J, Evans JHC. Liver failure and Epstein-Barr virus infection. Arch Dis Child, 1988; 63: 432-445.
2. Markin RS. Manifestations of Epstein-Barr virus associated disorders in liver. Liver 1994; 14: 1-13.
3. Wick MJ, Woronzoff-Dashkoff KP, McGlennen RC. The molecular characterization of fatal infectious mononucleosis Am J Clin Pathol 2002; 117: 582-588
4. ) Cohen JI. Epstein-Barr virus infection. N Engl J Med 2000; 343: 481-492.
5. Obel N, Madsen MH, Kangro H. Serological and clinical findings in patients with serological evidence of reactivated Epstein-Barr virus infection. APMIS 1996; 104: 424-428.
6. Stevens SJ, Vervoort MB, Van Den Brule AJ, Meenhorst PL, Mejier CJ, Middledorp JM. Monitoring of Epstein Barr DNA load in peripheral blood by quantitative competitive PCR. J Clin Microbiol 1999; 37: 2852-2857.
7. Aalto SM, Linnavuori K, Peltola H, et al. Immunoreactivation of Epstein-Barr virus due to Cytomegalovirus primary infection. J Med Virol 1998; 56: 186-191.
8. Rahman MA, Kingsley LA, Atchinson RW, et al. Reactivation of Epstein-Barr virus during early infection with human immunodeficiency virus. J Clin Microbiol 1991; 29: 1215-1220.
9. Palanduz A, Yildimark Y, Tehlan L, et al. Fulminant hepatic failure and autoimmune hemolytic anemia associated with Epstein Barr virus infection. J Infect 2002; 45: 96-98.
10. Ogawa J, Koike R, Sugihara T, et al. An autopsied case of chronic active Epstein Barr virus infection complicated in systemic lupus erythematous and antiphospholipid antibody syndrome. Nihon Rinsho Meneki Gakkai Kaishi 2002; 25: 458-465.
11. Papatheodoridis GV, Delladetsima JK, Kavallierou L, Kapranos N, Tassopoulos NC. Fulminant hepatitis due to Epstein Barr virus infection. J Hepatol 1995; 23: 348-350.
12. Baumgarten E, Herbst H, Schmitt M, Seeger KH, Schulte-Overberg U, Henze G. Life-threatening infectious mononucleosis: is it correlated with virus-induced T-cell proliferation? Clin Infect Dis 1994; 19: 152-156.
13. Hess G, Manns M, Hutteroth TH, Meyer Zum Buschenfelde KH. Discontinuation of immunosuppressive therapy in hepatitis B surface antigen-positive chronic hepatitis: effect on viral replication and on liver cell damage. Digestion 1987; 36: 47-54.